Karachi: Macter International Limited has announced the launch of TirzaTrim (Tirzepatide), a multidose pre-filled pen (PFP) for the management of Type 2 Diabetes Mellitus. The announcement, dated January 29, 2026, marks a significant development in the company’s biotechnology portfolio.

The newly launched TirzaTrim is designed as a dual receptor agonist targeting Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1). It is intended to improve glycemic control and promote weight reduction in patients, offering a next-generation incretin-based therapy with substantial clinical benefits in cardio-metabolic care.

According to information available from the Pakistan Stock Exchange (PSX), this launch underscores Macter’s commitment to enhancing its position in advanced injectable drug delivery systems and complex biologics within the Pakistani market. By introducing TirzaTrim, Macter aims to provide innovative, patient-centric therapies and broaden access to treatments that meet global standards.

The introduction of this product represents an important milestone for Macter International Limited, further solidifying its role in providing advanced healthcare solutions in Pakistan. The company’s focus on expanding its biotechnology offerings is aligned with its strategy to deliver impactful healthcare innovations to the local community.